<DOC>
	<DOCNO>NCT00004643</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate toxicity cytarabine patient refractory systemic lupus erythematosus . II . Evaluate objective disease parameter , include serum complement level , anti-DNA antibody titer , sedimentation rate , systemic lupus activity measure patient .</brief_summary>
	<brief_title>Phase II Pilot Study Cytarabine Refractory Systemic Lupus Erythematosus</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Subcutaneous cytarabine give 5 day . Patients re-treated every 4 week maximum 3 course ; relapse prior second course re-treated every 3 week .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Clinically document active systemic lupus erythematosus demonstrate least 4 revise diagnostic criterion Unresponsive conventional therapy nonsteroidal antiinflammatory drug ( NSAIDs ) , topical corticosteroid , antimalarial Intolerable side effect corticosteroids immunosuppressive drug Failure immunosuppressive require No lifethreatening disease , e.g . : Lupus cerebritis Rapidly progressive glomerulonephritis Prior/Concurrent Therapy No concurrent DNA synthesis inhibitor , NSAIDs , prednisone continue study Patient Characteristics Hematopoietic : WBC least 2000 ; Platelets least 100,000 Renal : Creatinine clearance least 20 mL/min Other : No major infection within 2 week prior entry Negative pregnancy test require fertile woman Effective contraception require fertile woman . Advised men 75 day therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic lupus erythematosus</keyword>
</DOC>